ENTA News and Press, Enanta Pharmaceuticals Inc. From 11/21/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two upcoming confere...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and year ended September 30,...

OCA, Intercept’s only commercialized product, is undergoing an FDA investigation on its safety. Once battered by a failed FDA approval for OCA as a NASH therapy, the stock slumped to trade near a 52-week low last week. The top-line growth hurt by the pandemic’s impac...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at t...

Axsome reports positive data from Major Depressive Disorder study. Penumbra suffers setback as new catheter falters. Enanta begins NASH clinical study for EDP-297. For further details see: Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma ...

Enanta Pharmaceuticals ( ENTA +2.0% ) has dosed the first patient in its Phase 1 trial of EDP-297, potent and targeted follow-on farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis (NASH). More news on: Enanta Pharmaceuticals, Inc., Healthcare sto...

-- Initial clinical data including safety, tolerability and pharmacokinetics expected in 2Q 2021 – Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today ann...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in three upcoming virtual con...

Fortress Biotech reports positive data from CUTX-101 Fortress Biotech Inc. ( FBIO ) reported positive topline clinical efficacy data for CUTX-101. The trial is being conducted by its partner company Cyprium Therapeutics. The data showed the drug candidate brought about statistically sign...